AzTrials
AzTrials

Hypotension and ShockSPITFIRENCT04760977

Prehospital Management of Hypotensive Trauma in HEMS

An observational study of Hypotension and Shock and Wounds and Injuries, run by Azienda Usl di Bologna at 16 sites in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Up to today, inadequate evidences and knowledge exist about the best prehospital management of hypotensive trauma patients and its clinical consequence on the in-hospital recovery and mortality. Read more about this study

Who is it for?
Ages 18 years and older
How many people
1,268 participants
Where
16 sitesItaly
Study dates
1 May 2021to 31 Mar 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The population object of study is represented by all the trauma patients managed by the HEMS crew that are experiencing a probable or obvious haemorragic shock

Who may be able to join

  • Age > 18 years
  • Witnessed traumatic event managed by HEMS
  • Shock at first evaluation (Systolic blood pressure < 90 mmHg)
  • Suspect or obvious ongoing haemorrage

Who cannot join

  • Patients in cardiac arrest at HEMS arrival in which resuscitation is not started or interrupted by HEMS crew

Trial locations and contacts

16 sites in 1 country.

16 sites in 1 country

Italy16 sites
  • Ospedale di Alessandria

    Alessandria

  • Base HEMS Aosta

    Aosta

  • Ospedale di Bolzano

    Bologna

  • Base HEMS Borgo Sesia

    Borgosesia

  • Base HEMS Cuneo-Levaldigi

    Cuneo

  • Ospedale Careggi Firenze

    Florence

  • Ospedale di Siena, Ospedale di Pisa

    Grosseto

  • Ospedale di Siena, Ospedale di Pisa

    Massa

  • Ospedale di Padova

    Padova

  • Pavullo HEMS base

    Pavullo nel Frignano, Italy

  • Pieve di Cadore HEMS base

    Pieve di Cadore, Italy

  • Ospedale di Torino

    Torino

  • Base HEMS Trento

    Trento

  • Treviso hospital

    Treviso, Italy

  • Udine FVG

    Udine, Italy

  • Ospedale di Verona Borgo Trento

    Verona

Other trials in Italy

About this study

Up to today, inadequate evidences and knowledge exist about the best prehospital management of hypotensive trauma patients and its clinical consequence on the in-hospital recovery and mortality.

Also new emerging therapies such as prehospital blood transfusion and REBOA (resuscitative endovascular balloon occlusion of the aorta) are lacking strong evidences in, eventually, reducing hospital mortality and improving outcomes.

Read more

Moreover, prehospital emergency medicine is throughout Italy an heterogeneous system that has no unique standard operating procedures and, even among HEMS (helicopter emergency medical service), management and therapies on complex trauma patients may vary upon local policies.

With this study we aim to enroll hypotensive trauma patients and study factors of prehospital rescue that can be associated with in-hospital mortality and recovery, eventually even with hospital outcome. For each patients data as demographic, kind of trauma (mechanism, injury scores), therapies and maneuvers will be recorded and then analyzed in comparison with in-hospital data such as need for transfusion, ABG parameters, length of stay (in-ward and ICU), need of therapies like invasive ventilation and renal replacement therapy, recovery and outcome

Keywords
Transportation of Patients, Wounds and Injuries, Emergencies, Critical Care
Medical subject headings
Hypotension, Shock, Wounds and Injuries, Emergencies

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT04760977
Study groupRoleWhat they receive
patients received prehospital blood productspatients received prehospital blood products
patients did not received any prehospital blood productspatients did not received any prehospital blood products

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. All-cause mortality at 24 hours

    Measured: 24 hours from first prehospital physician contact

  2. All-cause mortality at 7 days

    Measured: 7 days from first prehospital physician contact

  3. All-cause mortality at 30 days

    Measured: 30 days from first prehospital physician contact

Secondary outcomes (4)
  1. survival from prehospital to hospital admmission

    Measured: 1 day

  2. Hospital length of stay

    Measured: 6 months

  3. Blood products transfused during the first 24 hours after hospital admission

    Measured: 24 hours

  4. Transport time

    time from dispatch to hospital admission (if any)

    Measured: 24 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Feb 2021
  2. Study start1 May 2021
  3. Primary completion31 Mar 2026
  4. Study completion31 Mar 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,268 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04760977
Sponsor's protocol ID
959-2020-OSS-AUSLBO
Acronym
SPITFIRE
Status last verified
Oct 2026
First submitted
16 Feb 2021
Last updated
8 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Tartaglione M, Carenzo L, Gamberini L, Lupi C, Giugni A, Mazzoli CA, Chiarini V, Cavagna S, Allegri D, Holcomb JB, Lockey D, Sbrana G, Gordini G, Coniglio C; SPITFIRE Study Collaborators. Multicentre observational study on practice of prehospital management of hypotensive trauma patients: the SPITFIRE study protocol. BMJ Open. 2022 May 30;12(5):e062097. doi: 10.1136/bmjopen-2022-062097.

    PubMed 35636792
  • Brown JB, Sperry JL, Fombona A, Billiar TR, Peitzman AB, Guyette FX. Pre-trauma center red blood cell transfusion is associated with improved early outcomes in air medical trauma patients. J Am Coll Surg. 2015 May;220(5):797-808. doi: 10.1016/j.jamcollsurg.2015.01.006. Epub 2015 Jan 24.

    PubMed 25840537
  • Smith IM, James RH, Dretzke J, Midwinter MJ. Prehospital Blood Product Resuscitation for Trauma: A Systematic Review. Shock. 2016 Jul;46(1):3-16. doi: 10.1097/SHK.0000000000000569.

    PubMed 26825635
  • Spahn DR, Bouillon B, Cerny V, Duranteau J, Filipescu D, Hunt BJ, Komadina R, Maegele M, Nardi G, Riddez L, Samama CM, Vincent JL, Rossaint R. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care. 2019 Mar 27;23(1):98. doi: 10.1186/s13054-019-2347-3.

    PubMed 30917843
  • Powell EK, Hinckley WR, Gottula A, Hart KW, Lindsell CJ, McMullan JT. Shorter times to packed red blood cell transfusion are associated with decreased risk of death in traumatically injured patients. J Trauma Acute Care Surg. 2016 Sep;81(3):458-62. doi: 10.1097/TA.0000000000001078.

    PubMed 27050884
  • Brohi K, Gruen RL, Holcomb JB. Why are bleeding trauma patients still dying? Intensive Care Med. 2019 May;45(5):709-711. doi: 10.1007/s00134-019-05560-x. Epub 2019 Feb 11. No abstract available.

    PubMed 30741331

Questions about this trial

What is this clinical trial studying?

An observational study of Hypotension and Shock and Wounds and Injuries, run by Azienda Usl di Bologna at 16 sites in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 16 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

All-cause mortality at 24 hours (time frame: 24 hours from first prehospital physician contact). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04760977, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in